Brazilian health agency queried by CADE in review of União Química-Bayer deal
Brazil’s competition authority has queried the Brazilian Health Regulatory Agency (Anvisa) regarding União Química Farmacêutica Nacional's proposed acquisition of manufacturing, commercialization, and intellectual property rights for the hormonal therapy drugs Primogyna...To view the full article, register now.
Already a subscriber? Click here to view full article